WEE1 and fragile X syndrome: Other examples of hiPSC-based drug testing include mTORC1 inhibition for TSC (Winden et al., 2019), IGF-1 treatment for RTT (Tang et al., 2016) and protein kinase inhibitor in FXS (Das Sharma et al., 2020).